To explain these findings, a critical mechanistic case report by Kiuchi et al. has highlighted that the SGLT2 inhibitor ipragliflozin, in a patient with chronic heart failure and diabetes mellitus, resulted in reduced cardiac sympathetic nerve hyperactivity. Here, SLC5A2 is linked to diabetes mellitus.